KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kura Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$9.36+0.28 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $831.68M
- P/E (TTM)
- –
- Dividend yield
- –
Kura Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q2 25 | Q1 25 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Collaboration revenue | $11.75M | $12.50M | $15.29M | $14.11M | 56.3% | -23.1% |
| Collaboration Revenue [Member] | $11.75M | $12.50M | $15.29M | $14.11M | 56.3% | -23.1% |
| Product [Member] | $9.12M | $5.77M | $0 | $0 | 43.7% | – |
By region
From the segment and revenue-disaggregation notes of Kura Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.